Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Large Billy Madison O' Doyle Rules T-Shirt - Navy/White
Popular Articles

Discovery Of New Trigger For Chronic Inflammation In Rheumatoid Arthritis
A signal molecule made by the human body that triggers the immune system into action may be important in rheumatoid arthritis, according to new research published in Nature Medicine. The authors of the study, from Imperial College London, say that if scientists could block this signal, it may be possible to develop more effective arthritis treatments.

"Nature" And "Nurture" Variables Early Predictors Of AMD
Like many diseases, causes for age-related macular degeneration (AMD) can be categorized as either "nature" or "nurture". Researchers think these factors, when used in the proper model, can be strong predictors of the disease.
News of the day
Experts Call On Colleagues To Drive Optimal Care For All Post-Mi Patients In The UK
Today experts from the Primary Care Cardiovascular Society (PCCS) and HEART UK - the Cholesterol Charity, are calling upon primary care clinicians to embrace new guidance designed to support optimal care and treatment of post-myocardial infarction (MI) patients. Published in the latest issue of the British Journal of Cardiology, the guidance is unique as it is aligned to both patients and primary care, thereby recognising the vital role of empowering patients and their families in achieving the best possible clinical outcomes.2
Public Health

BioPartners GmbH Withdraws Its Application For Biferonex (interferon Beta-1a)

The European Medicines Agency has been formally notified by BioPartners GmbH of its decision to withdraw its application for Biferonex (interferon beta-1a), 6 million-international-unit solution for injection, prefilled syringes for subcutaneous administration. Biferonex was expected to be used to treat patients with relapsing-remitting multiple sclerosis characterised by two or more exacerbations of neurological symptoms in the previous two years. The application for the marketing authorisation for Biferonex was submitted to the Agency on 24 July 2007. On 19 February 2009, the Agency"s Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation. Following this, the company requested a re-examination of the opinion, which was under review by the CHMP at the time of the withdrawal. The company stated in its official letter that its decision to withdraw the application was based on the fact that the additional information provided in support of the re÷¬examination had not changed the Committee"s view on the benefit-risk balance of Biferonex. More information about Biferonex and the state of the scientific assessment at the time of withdrawal will be made available in a question-and-answer document. This document, together with the withdrawal letter from the company, will be published on the Agency"s website after the next CHMP meeting of 22-25 June 2009. Notes 1. Withdrawal of an application does not prejudice the possibility of a company making a new application at a later stage. 2. This press release, together with other information on the work of the Agency, can be found on the Agency"s website: http://www.emea.europa.eu EMEA


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009